Thrombophilia Profile at Chughtai Lab

Thrombophilia Profile at Chughtai Lab

A Thrombophilia Profile is a comprehensive panel of specialized laboratory investigations designed to evaluate a patient's predisposition to pathological blood clot formation, a clinical state known as hypercoagulability or thrombophilia. Under normal physiological conditions, the human body maintains a delicate balance between hemostasis (the prevention of blood loss through clot formation) and fibrinolysis (the dissolution of clots to maintain vascular patency). When this homeostatic equilibrium is disrupted by genetic mutations or acquired clinical conditions, the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis increases significantly. The Thrombophilia Profile at Chughtai Lab assesses these pathways with high diagnostic precision.

This specialized profile evaluates the blood plasma for deficiencies in natural physiological anticoagulants, the presence of abnormal clotting factors, genetic mutations, and autoimmune antibodies that target phospholipids. The diagnostic panel typically includes functional assays, immunological assays, and molecular genetic testing. By analyzing these parameters, hematologists and physicians can determine whether a patient's thrombotic event was triggered by an underlying systemic predisposition. This information is critical for determining the duration and intensity of anticoagulant therapy, assessing the risk of recurrent thrombosis, and guiding clinical management during high-risk periods such as pregnancy, major surgery, or prolonged immobilization.

Chughtai Lab utilizes advanced, fully automated coagulation analyzers and molecular diagnostic platforms to perform these complex assays. The laboratory employs photo-optical and mechanical clot detection technologies for functional assays, Enzyme-Linked Immunosorbent Assay (ELISA) or Chemiluminescent Immunoassay (CLIA) for serological markers, and Polymerase Chain Reaction (PCR) for genetic mutation analysis. This multi-platform approach ensures that every component of the Thrombophilia Profile meets international standards of analytical sensitivity and specificity, providing clinicians with reliable, actionable data to guide patient care across Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is paramount for the clinical validity of a Thrombophilia Profile, as numerous external factors, medications, and physiological states can profoundly alter coagulation parameters and lead to false-positive or false-negative results. Patients must strictly adhere to the following preparation guidelines:

• Anticoagulant Therapy Discontinuation: This is the most critical preparation step. Active therapy with oral anticoagulants (such as Warfarin), direct oral anticoagulants (DOACs like Rivaroxaban, Apixaban, or Dabigatran), or heparin therapies (UFH or LMWH) will interfere with functional assays (e.g., Protein C, Protein S, Antithrombin III, and Lupus Anticoagulant). Patients must consult their prescribing physician regarding the safe temporary discontinuation of these medications. Typically, testing should be delayed for at least 2 weeks after stopping Warfarin and at least 48 to 72 hours after stopping DOACs.
• Timing Post-Thrombotic Event: Testing should ideally not be performed during an acute thrombotic episode (such as an active DVT or PE). The acute inflammatory response and consumption of clotting factors during an active clot can artificially lower the levels of Antithrombin, Protein C, and Protein S, leading to an incorrect diagnosis of hereditary deficiency. It is clinically recommended to wait at least 3 to 6 months after the acute event before undergoing a thrombophilia screen.
• Fasting Requirements: A fasting period of 8 to 12 hours is generally recommended prior to sample collection. While basic genetic tests do not require fasting, certain metabolic components of the profile, such as Homocysteine levels, require a fasting state to ensure accurate baseline measurements. Only plain water is permitted during this fasting window.
• Avoidance of Estrogen-Containing Medications: Oral contraceptive pills, hormone replacement therapy (HRT), and pregnancy can significantly alter the levels of coagulation proteins, particularly decreasing free Protein S levels and increasing resistance to Activated Protein C. If possible, and under medical supervision, these therapies should be discontinued for 4 to 6 weeks prior to testing.
• General Health Status: The patient should be in their baseline state of health. Acute illnesses, active infections, inflammatory flare-ups, or recent surgical procedures can elevate acute-phase reactants (such as Fibrinogen and Factor VIII), which can mask underlying deficiencies or interfere with coagulation assays.

During the Procedure

The collection of blood samples for a Thrombophilia Profile is a standardized venipuncture procedure performed by trained phlebotomists at Chughtai Lab. Because this profile comprises multiple distinct assays, several tubes of blood must be collected in a specific sequence (known as the "order of draw") to prevent cross-contamination of additives:

• Venipuncture Process: The phlebotomist will locate a suitable vein, typically in the antecubital fossa of the arm. The area is thoroughly cleansed with an antiseptic solution. A tourniquet is applied briefly to facilitate vein visualization, but it is released as soon as blood flow is established to prevent hemoconcentration, which can artificially alter coagulation times.
• Tube Types and Anticoagulants: The phlebotomist will draw blood into multiple tubes. Light blue-top tubes containing buffered sodium citrate (3.2%) are used exclusively for coagulation assays (Protein C, Protein S, Antithrombin, Lupus Anticoagulant). It is clinically vital that these tubes are filled completely to the marked line to maintain the exact 9:1 ratio of blood to anticoagulant; underfilled tubes will yield inaccurate, unreportable results. Lavender-top tubes containing EDTA are collected for molecular genetic testing (Factor V Leiden and Prothrombin gene mutations). Gold or red-top serum separator tubes are collected for immunological assays (Anti-Cardiolipin and Anti-Beta-2 Glycoprotein I antibodies).
• Post-Collection Handling: Immediately after filling, each tube is gently inverted 5 to 10 times to ensure thorough mixing of the blood with the anticoagulant or clot activator. The sodium citrate tubes are promptly transported to the laboratory department, where they undergo double centrifugation to obtain platelet-poor plasma (platelet count < 10 x 10^9/L), which is essential because residual platelets can release phospholipids and neutralize lupus anticoagulants or alter other clotting assays.
• Duration and Patient Experience: The entire venipuncture procedure takes approximately 5 to 10 minutes. Patients may feel a mild, brief pinch as the needle is inserted. After the needle is withdrawn, firm pressure is applied to the puncture site for several minutes to prevent hematoma formation, especially in patients with a history of bleeding or those recently on anticoagulants. A sterile adhesive bandage is then applied.

When is a Thrombophilia Profile Performed?

Unexplained Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)

A primary indication for a Thrombophilia Profile is the occurrence of an unprovoked venous thromboembolic event. When a patient develops a deep vein thrombosis (typically presenting as unilateral leg swelling, warmth, erythema, and pain) or a life-threatening pulmonary embolism (characterized by sudden dyspnea, pleuritic chest pain, tachypnea, and tachycardia) without any obvious provoking factors—such as major orthopedic surgery, severe trauma, prolonged immobilization, or active malignancy—an underlying hypercoagulable state is highly suspected. Identifying a specific thrombophilic defect helps clinicians assess the long-term risk of recurrence and decide whether the patient requires indefinite, lifelong anticoagulation therapy rather than a standard 3-to-6-month course.

Recurrent Pregnancy Loss or Obstetric Complications

Thrombophilia is a well-established cause of adverse pregnancy outcomes. During pregnancy, the maternal body naturally shifts toward a hypercoagulable state to prevent excessive bleeding during delivery. However, if an underlying hereditary or acquired thrombophilia is present, this hypercoagulability can become pathological, leading to microvascular thrombosis within the developing placental circulation. This can cause placental insufficiency, leading to recurrent early pregnancy losses (typically three or more consecutive first-trimester miscarriages), unexplained late-term fetal demise, severe preeclampsia, intrauterine growth restriction (IUGR), or placental abruption. Diagnosing conditions like Antiphospholipid Syndrome (APS) or Factor V Leiden allows obstetricians to initiate prophylactic low-molecular-weight heparin (LMWH) and low-dose aspirin therapy to improve live birth rates.

Thromboembolism at a Young Age (Under 50 Years)

Venous thromboembolism is relatively uncommon in young, healthy individuals. When a patient under the age of 50 develops a DVT, PE, or arterial thrombosis (such as an ischemic stroke or myocardial infarction) in the absence of traditional cardiovascular risk factors, a hereditary thrombophilia is highly probable. Genetic mutations such as the Factor V Leiden mutation or the Prothrombin G20210A mutation, as well as hereditary deficiencies of Protein C, Protein S, or Antithrombin, are frequently identified in this demographic. Early diagnosis in young patients is crucial, as it prompts counseling regarding lifestyle modifications, avoidance of estrogen-containing medications, and the implementation of thromboprophylaxis during future high-risk scenarios.

Thrombosis in Unusual Anatomical Sites

While the deep veins of the lower extremities and the pulmonary arteries are the most common sites for thrombosis, clots can occasionally form in atypical vascular beds. Thrombosis occurring in the cerebral venous sinuses, portal vein, hepatic veins (Budd-Chiari syndrome), mesenteric veins, renal veins, or upper extremity veins is highly suggestive of an underlying systemic hypercoagulable disorder. A comprehensive Thrombophilia Profile is indicated in these patients to identify the driving pathophysiological mechanism, which is often a combination of inherited defects or acquired conditions like Antiphospholipid Syndrome or underlying myeloproliferative neoplasms.

Strong Family History of Hereditary Clotting Disorders

Asymptomatic individuals who have a first-degree relative (parent, sibling, or child) with a documented history of severe, recurrent, or early-onset venous thromboembolism, or a known hereditary thrombophilic defect, may be candidates for target screening. While routine screening of the general population is not clinically indicated, testing selected individuals with a strong family history helps in personalized risk assessment. Knowing that one carries a genetic mutation like Factor V Leiden or a natural anticoagulant deficiency allows for proactive clinical management, such as administering prophylactic anticoagulation during major surgeries, postpartum periods, or long-haul travel to prevent the first thrombotic event.

What Does a Thrombophilia Profile Detect?

The Thrombophilia Profile at Chughtai Lab is designed to detect a wide array of inherited and acquired molecular abnormalities that predispose a patient to thrombosis. The profile evaluates the following specific parameters and clinical findings:

• Factor V Leiden Mutation: A genetic mutation in the F5 gene that renders Factor V resistant to inactivation by Activated Protein C (APC), leading to sustained thrombin generation.
• Activated Protein C (APC) Resistance: A functional assay that measures the sensitivity of the coagulation pathway to APC; a low ratio indicates resistance, most commonly caused by the Factor V Leiden mutation.
• Prothrombin (Factor II) G20210A Mutation: A genetic variant in the prothrombin gene that leads to elevated circulating levels of prothrombin (Factor II), a precursor to thrombin, thereby increasing clot risk.
• Protein C Activity: A functional assay measuring the level of active Protein C, a vitamin K-dependent natural anticoagulant that degrades active Factors Va and VIIIa.
• Protein C Antigen: An immunological assay that quantifies the physical amount of Protein C protein, helping to differentiate between Type I (quantitative) and Type II (qualitative) deficiencies.
• Protein S Activity: A functional assay evaluating the activity of Protein S, which serves as an essential cofactor for Activated Protein C.
• Free Protein S Antigen: Measures the unbound, biologically active form of Protein S in the plasma, which is the clinically relevant parameter for diagnosing deficiency.
• Total Protein S Antigen: Measures both free Protein S and the form bound to C4b-binding protein to characterize the subtype of deficiency.
• Antithrombin III (AT III) Activity: A functional assay assessing the activity of Antithrombin, a potent serine protease inhibitor that neutralizes thrombin, Factor Xa, and other coagulation enzymes.
• Antithrombin III Antigen: Quantifies the total amount of Antithrombin protein to classify the deficiency as Type I (decreased synthesis) or Type II (functional defect).
• Lupus Anticoagulant (LA) Screen: A series of phospholipid-dependent clotting tests (such as the Dilute Russell's Viper Venom Time – dRVVT) used to detect autoantibodies that prolong clotting times in vitro but promote thrombosis in vivo.
• Lupus Anticoagulant Confirm: A confirmatory test where excess phospholipid is added to neutralize the antibodies, proving that the initial prolongation was phospholipid-dependent.
• Anti-Cardiolipin Antibodies (IgG): An ELISA-based test detecting IgG autoantibodies directed against cardiolipin-protein complexes, a key marker for Antiphospholipid Syndrome (APS).
• Anti-Cardiolipin Antibodies (IgM): Detects IgM class antibodies against cardiolipin, indicating acute or ongoing autoimmune activity associated with APS.
• Anti-Beta-2 Glycoprotein I Antibodies (IgG): Measures IgG antibodies targeting beta-2 glycoprotein I, which are highly specific for the diagnosis of clinically significant APS and pregnancy complications.
• Anti-Beta-2 Glycoprotein I Antibodies (IgM): Measures the IgM subclass of these highly specific antiphospholipid antibodies.
• Fasting Plasma Homocysteine: Evaluates the concentration of homocysteine in the blood; elevated levels (hyperhomocysteinemia) can cause vascular endothelial damage and increase thrombotic risk.
• Factor VIII Activity: Measures the functional activity of clotting Factor VIII; persistently elevated levels are an independent risk factor for venous thrombosis.
• Factor IX Activity: Evaluates Factor IX levels, where elevated concentrations can contribute to an increased risk of thromboembolism.
• Factor XI Activity: Assesses Factor XI levels, which, when elevated, are associated with a higher risk of venous thrombosis.
• Fibrinogen Activity (Clauss Method): Measures the functional level of fibrinogen, the precursor to fibrin; high levels act as an acute-phase reactant and increase blood viscosity and clot risk.
• Methylenetetrahydrofolate Reductase (MTHFR) C677T Mutation: A genetic test for a common variant that, when homozygous, can lead to elevated homocysteine levels, particularly in the presence of folate deficiency.
• MTHFR A1298C Mutation: Another genetic variant in the MTHFR gene that can contribute to altered folate metabolism and mild hyperhomocysteinemia.
• Dysfibrinogenemia: Detected through a discrepancy between functional fibrinogen activity and immunological fibrinogen antigen levels, indicating structurally abnormal fibrinogen.
• Acquired Protein C/S Deficiencies: Differentiates inherited deficiencies from acquired states caused by severe hepatic disease, vitamin K deficiency, or active consumption during disseminated intravascular coagulation (DIC).

Turnaround Time and Report Access at Chughtai Lab

Because a Thrombophilia Profile consists of highly specialized, complex assays—ranging from functional coagulation kinetics to molecular genetic sequencing—the turnaround time is longer than that of routine hematological tests. At Chughtai Lab, individual components such as basic coagulation assays (Protein C, S, and Antithrombin) are typically processed within 48 to 72 hours. However, the complete profile, including genetic mutation analysis (Factor V Leiden, Prothrombin gene) and specialized antiphospholipid antibody panels, generally requires 5 to 7 working days for final verification and reporting.

Chughtai Lab offers seamless, digital report access to ensure patients and their referring physicians receive results promptly. Once the clinical pathologist reviews and signs off on the final report, an automated SMS notification is sent to the patient's registered mobile number containing a direct link to download the report in PDF format. Patients can also access their complete diagnostic history via the official Chughtai Lab Mobile App or by logging into the patient portal on the official Chughtai Lab website. For convenience, printed reports can be collected from any Chughtai Lab collection center nationwide, or delivered directly to the patient's home through their dedicated report delivery service.

Thrombophilia Profile Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Factor V Leiden (G1691A) Mutation	Wild Type (Normal / No Mutation)	Heterozygous (One mutated allele; 3-8 fold increased clot risk) or Homozygous (Two mutated alleles; up to 80-fold increased risk)
Prothrombin (G20210A) Mutation	Wild Type (Normal / No Mutation)	Heterozygous or Homozygous mutation (Leads to elevated prothrombin levels and increased VTE risk)
Protein C Activity	70% – 140% (May vary slightly by assay)	Decreased activity (<70%), indicating hereditary deficiency (Type I or II) or acquired deficiency (liver disease, Warfarin therapy)
Free Protein S Antigen	65% – 140% (Gender-specific ranges apply)	Decreased free antigen levels, indicating hereditary deficiency or acquired states (pregnancy, oral contraceptives, estrogen therapy)
Antithrombin III Activity	80% – 120%	Decreased activity (<80%), indicating hereditary deficiency or acquired depletion (heparin therapy, nephrotic syndrome, severe liver disease)
Lupus Anticoagulant (dRVVT Screen/Confirm)	Negative (Ratio < 1.2)	Positive (Ratio >= 1.2 with correction upon addition of excess phospholipid), indicating Antiphospholipid Syndrome
Anti-Cardiolipin Antibodies (IgG/IgM)	Negative (< 12 GPL/MPL units)	Positive (> 12 GPL/MPL units); persistently positive results 12 weeks apart confirm Antiphospholipid Syndrome
Plasma Homocysteine (Fasting)	< 15 micromol/L	Elevated levels (> 15 micromol/L), indicating hyperhomocysteinemia (genetic MTHFR defects, B12/folate deficiency, or renal impairment)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Thrombophilia Profile?

• ISO 15189 Certified Laboratories: Chughtai Lab operates under strict international quality management standards, ensuring the highest level of analytical accuracy and reliability for complex hematological testing.
• Advanced Molecular Diagnostics: The laboratory utilizes state-of-the-art Real-Time PCR platforms to perform genetic mutation analyses, providing definitive genotyping for Factor V Leiden and Prothrombin variants.
• Expert Pathologist Supervision: All specialized coagulation profiles are supervised, reviewed, and interpreted by highly qualified consultant hematologists and clinical pathologists.
• Convenient Home Sampling: Patients can avoid travel and have their blood samples collected in the comfort of their homes by trained phlebotomists, adhering to strict cold-chain sample transport protocols.
• Nationwide Network: With hundreds of collection centers across Lahore, Karachi, Islamabad, and other major cities, Chughtai Lab offers unmatched accessibility for patients throughout Pakistan.
• Robust Digital Infrastructure: Patients can easily access, download, and share their diagnostic reports via the user-friendly Chughtai Lab Mobile App or online web portal.
• Comprehensive Panel Availability: Chughtai Lab offers the complete spectrum of both functional and immunological assays required for a thorough thrombophilia workup under one roof.
• Strict Pre-Analytical Quality Control: The laboratory implements rigorous protocols for sample handling, centrifugation, and temperature control, which are vital for preserving fragile coagulation factors.